Trial · NCT04023526
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With Complete Remission (CR) | Up to 3 years and 5 months | Intention-to-treat (ITT) | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With CR With Partial Hematological Recovery (CRh) | Up to 3 years and 5 months | ITT | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With CR Plus CRh | Up to 3 years and 5 months | ITT | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With CR With Incomplete Recovery (CRi) | Up to 3 years and 5 months | ITT | percentage of participants | NUMBER |
| SECONDARY | Overall Response Rate (ORR) | Up to 3 years and 5 months | ITT | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With CR Without MRD | Up to 3 years and 5 months | ITT | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percentage of Participants With Negative MRD Who Achieved CR, CRh, CRi, or Morphologic Leukemia-free State (MLFS) | Up to 3 years and 5 months | |||
| SECONDARY | Time to First Response | Up to 3 years and 5 months | Responder population: Participants who achieved CR, CRh or CRi | Months | MEDIAN |
| SECONDARY | Duration of First Response | Up to 3 years and 5 months | Responder population: Participants who achieved CR, CRh or CRi | Months | MEDIAN |
| SECONDARY | Red Blood Cell (RBC) and/or Platelets Transfusion Independence | Up to 3 years and 5 months | ITT | percentage of participants | NUMBER |
| SECONDARY | Cusatuzumab Minimum Serum Concentration (Cmin) | Cycle 1 Day 3 | All participants with available serum concentrations per intervention group. | micrograms/milliliter | MEAN |
| SECONDARY | Maximum Serum Concentration (Cmax) of Cusatuzumab | Cycle 1 Day 3 | All participants with available serum concentrations per intervention group | micrograms/milliliter | MEAN |
| SECONDARY | Number of Participants With Anti-cusatuzumab Antibodies | Up to 3 years and 5 months | Participants with evaluable samples. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04023526/outcomes